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Genetic Analysis of Dystrophin Gene for Affected Male and 
Female Carriers with Duchenne/Becker Muscular Dystrophy  
in Korea
Duchenne and Becker muscular dystrophy (DMD/BMD) are X-linked recessive disorders 
caused by mutation in dystrophin gene. We analyzed the results of a genetic test in 29 
DMD/BMD patients, their six female relatives, and two myopathic female patients in 
Korea. As the methods developed, we applied different procedures for dystrophin gene 
analysis; initially, multiplex polymerase chain reaction was used, followed by multiplex 
ligation-dependent probe amplification (MLPA). Additionally, we used direct DNA 
sequencing for some patients who had negative results using the above methods. The 
overall mutation detection rate was 72.4% (21/29) in DMD/BMD patients, identifying 
deletions in 58.6% (17/29). Most of the deletions were confined to the central hot spot 
region between exons 44 and 55 (52.9%, 7/19). The percentage of deletions and 
duplications revealed by MLPA was 45.5% (5/11) and 27.2% (3/11), respectively. Using the 
MLPA method, we detected mutations confirming their carrier status in all female relatives 
and symptomatic female patients. In one patient in whom MLPA revealed a single exon 
deletion of the dystrophin gene, subsequent DNA sequencing analysis identified a novel 
nonsense mutation (c.4558G > T; Gln1520X). The MLPA assay is a useful quantitative 
method for detecting mutation in asymptomatic or symptomatic carriers as well as DMD/
BMD patients.
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INTRODUCTION
Duchenne muscular dystrophy (DMD; MIM 310200) and Becker 
muscular dystrophy (BMD; MIM 300376) are allelic X-linked 
recessive disorders that are caused by mutation of the DMD 
gene located at Xp21 (1). DMD is the most common muscle 
disease in children, with a reported incidence of 1:3,500 live 
born males (2). 
  The dystrophin gene is the largest of the identified human 
genes, spanning 2.4 Mb of a genomic sequence and correspond-
ing to about 0.1% of the total human genome (1, 3). The gene 
contains 79 exons encoding a 14,000 bp messenger RNA tran-
script that is translated into the protein dystrophin (1, 3). The 
majority of identified mutations are deletions, accounting for 
approximately 60%-65% of DMD and 85% of BMD mutations, 
and duplications have been observed in 5%-15% (1, 3, 4). The 
remaining cases may be caused by small mutations such as mi-
crodeletions, microinsertions, point mutations, or splicing mu-
tations (1, 5).
  There are many methods for the detection of dystrophin gene 
mutations including multiplex polymerase chain reaction (PCR), 
Southern blotting, quantitative real time PCR, fluorescence in 
situ hybridization (FISH), and sequencing for point mutations 
(3, 5-7). Recently, multiplex ligation-dependent probe amplifi-
cation (MLPA) was developed for quantitative genomic screen-
ing of copy numbers variations at specific target sequences (8, 
9). However, there have been only a few reports of genetic anal-
ysis of the dystrophin gene in Korea. 
  In this study, we report the genetic analysis of the dystrophin 
gene and delineate genetic characteristics in DMD/BMD pa-
tients, their female carriers, and symptomatic female patients 
in Korea.
 
MATERIALS AND METHODS
Patients and female carriers
We performed mutation analysis in the dystrophin gene using 
multiplex PCR or MLPA at Samsung Seoul Hospital (Seoul, Ko-
rea) between January 2003 and November 2010. This study in-
cluded 29 DMD/BMD patients, six asymptomatic female rela-Lee BL, et al.  •  Dystrophin Gene Analysis for Affected Patients and Carriers in Korea
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tives, and two symptomatic female patients. All DMD/BMD pa-
tients were younger than 15 yr at the time of diagnosis and were 
clinically diagnosed based on typical clinical presentation, ele-
vated creatine kinase, and family history. Among the 29 male 
patients, four patients were clinically diagnosed with BMD who 
are ambulatory beyond age 12, and the remaining were diag-
nosed with DMD based on clinical severity and immunohisto-
chemical staining. A retrospective analysis of the medical re-
cords was conducted to determine the clinical and laboratory 
findings.
Genetic analysis
We applied multiplex PCR to 20 DMD/BMD patients between 
January 2003 and May 2006 and adopted the MLPA technique 
for 11 DMD/BMD patients, their six female relatives, and two 
symptomatic female patients between June 2006 and November 
2010.
Multiplex PCR
Genomic DNA was isolated from peripheral blood leukocytes 
using the Wizard genomic DNA purification kit according to 
the manufacturer’s instructions (Promega, Madison, WI, USA). 
Multiplex DNA amplification of the dystrophin gene was car-
ried out according to the techniques of Chamberlain et al. (10) 
and Beggs et al. (11) using two multiplex PCR assays for the am-
plification of ten primer pairs (exons 3, 4, 6, 8, 12, 13, 17, 19, 43-
52, 60, and promoter). The PCR products were separated on 3% 
agarose gel or 2% nusieve + 1% agarose gel.
Multiplex ligation-dependent probe amplification (MLPA)
The MLPA reaction was performed to screen exons of the dys-
trophin gene using the SALSA MLPA probe sets P034 and P035 
(MRC-Holland, Amsterdam, The Netherlands) according to the 
manufacturer’s instructions (12). The MLPA samples consisted 
of approximately 200 ng of genomic DNA. Ligation and ampli-
fication were carried out on an ABI 9600 Thermal Cycler. The 
PCR conditions included 33 cycles at 94°C for 30 sec, 60°C for 
30 sec, and 72°C for 60 sec, followed by a final extension at 72°C 
for 20 min to allow adequate probe hybridization with SALSA 
probe mix P034 (dystrophin gene exons 1-10, 21-30, 41-50, and 
61-70) and P035 (dystrophin gene exons 11-20, 31-40, 51-60, and 
71-79). All amplified fragments were separated using capillary 
electrophoresis on an ABI PRISM 3130 Genetic Analyzer. The 
area under the peak for each amplified fragment was measured 
and normalized in comparison with the peak areas of normal 
control individuals using GeneMarker software v.1.8 (SoftGen-
etics, State College, PA, USA). As the dystrophin gene is located 
on the X chromosome, deletions of one or more exons result in 
total absence of the corresponding MLPA amplification prod-
uct in male patients and a 30%-55% reduction in female carri-
ers (13). Duplications give an almost two-fold greater relative 
peak area in male patients and a 30%-55% increase in female 
carriers.
Confirmation of deletion of single exon
The MLPA results from male patients were initially assessed vi-
sually for the detection of deletion, which was represented as 
absence of the DMD specific peak. Absence of DMD peaks cor-
responding to two or more contagious exons was regarded as 
reliable, and no further investigation were performed. The ab-
sence of only one DMD peak in males was further examined by 
uniplex and multiplex PCR. If a deletion could not be confirmed 
by PCR, direct sequencing was performed to identify point mu-
tations using a BigDye Terminator Cycle Sequencing Ready Re-
action kit (Applied Biosystems) on the ABI 3100 Genetic analyz-
er (Applied Biosystems).
Ethics statement
This study protocol was reviewed and approved by the institu-
tional review board of the Samsung Medical Center (approval 
number: 2010-12-067-001). Written informed consent for ge-
netic study was obtained from each patient and participant.
 
RESULTS
Clinical characteristics 
The mean age of 25 DMD patients at the time of genetic testing 
was 5.1 ± 2.2 yr (10 months-7.7 yr), and the mean age of symp-
toms onset was 3.5 ± 2.2 yr (5 months-7.2 yr). The most common 
presenting symptom was muscle weakness, which was seen in 
13 patients (52.0%), followed by incidentally detected elevated 
hepatic enzymes in nine patients (36.0%). The remaining pa-
tients presented with developmental delay (n = 2) and abnor-
mal gait (n = 1). Nine of 25 patients (31.0%) had a family history 
of muscular dystrophy. Thirteen patients (52.0%) had gross mo-
tor developmental delay at the time of diagnosis, and six pa-
tients (24.0%) had a language delay. On physical examination, 
pseudohypertrophy of calf muscles was present in 21 patients 
(85.0%), and Gowers’ sign was observed in 17 patients (68.0%). 
The mean level of serum creatine kinase (CK) was 14,048 ±  
8,925 IU/L (4,605-39,318 IU/L), and the mean levels of liver en-
zymes aspartate transaminase (AST) and alanine transaminase 
(ALT) were 298 ± 177 IU/L (98-876 IU/L) and 411 ± 293 IU/L 
(84-1437 IU/L), respectively. Nine patients underwent a muscle 
biopsy. Eight patients showed a complete absence of dystrophin 
on immunohistochemical analysis, while a small amount of the 
protein was detected in one patient (case 13). The clinical sever-
ity of the patient was the same as the other patients; the patient 
was wheelchair-bound at the age of 10 yr.
  In cases of BMD, four patients came to medical attention at a 
mean age of 9.6 ± 3.0 yr. Mean age at diagnosis was 11.0 ± 3.7 yr. 
At that time, two patients complained of myalgia and muscle Lee BL, et al.  •  Dystrophin Gene Analysis for Affected Patients and Carriers in Korea
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cramps, while the other two patients showed asymptomatic el-
evated hepatic enzymes. Only one patient had a family of dys-
trophinoapthy. All patients maintained independent ambula-
tion. Gowers’ sign was observed in one patient (case 9). CK lev-
els were lower than in the DMD patients, with average values at 
diagnosis of 5,132 ± 4,284 IU/L (2,666-11,529 IU/L). The mean 
levels of AST and ALT were also lower in BMD patients at values 
of 107 ± 63 IU/L (69-200 IU/L) and 153 ± 34 IU/L (128-203 IU/
L), respectively. 
Clinical characteristics of female carriers 
Six female relatives of the four DMD patients were included in 
this study; four relatives were the mothers of affected patients, 
one was the sister of case 25, and one was the aunt of case 28. 
Additionally, this study included two symptomatic female car-
riers (case 34 and 37), aged 6.5 and 7.5 yr at the time of diagno-
sis. One patient (case 34) had strabismus and mild motor weak-
ness and was scheduled to undergo surgery at an ophthalmol-
ogy clinic. During the pre-surgical evaluation, an increase in he-
patic enzymes (AST/ALT) was found incidentally in that patient, 
and her serum CK level was 1,471 IU/L (reference: 24-204 IU/
L). The muscle biopsy revealed myopathic features, and MLPA 
showed a duplication of exons 61-77. The other symptomatic 
carrier (case 37) also had elevated hepatic enzymes and inter-
mittent leg pain. She was found to have pseudohypertrophy of 
the calf muscle upon physical examination. Her serum CK level 
was 3,854 IU/L, and the MLPA revealed a deletion of exon 68.
Molecular characteristics
Analysis of mutation in the dystrophin gene was performed with 
three different methods: multiplex PCR, MLPA, and direct DNA 
sequencing. In 15 patients (cases 1-20), multiplex PCR was per-
Table 1. Exon deletions and duplications detected by multiplex PCR and MLPA assay in DMD/BMD patients
Case Age
† (yr) Exon deletions Exon duplications Family history
‡ CK levels
§ (IU/L) Phenotype
  1 5 13 826 DMD
  2 1.2 52 + 11,020 DMD
  3 4 44-48 + 6,865 DMD
  4 0.6 45-47 4,605 DMD
  5 11 45-48 + 2,666 BMD
  6 0.4 46-51 14,421 DMD
  7 8 45-48 11,529 BMD
  8 3 8, 12, 13 10,354 DMD
  9 6.4 45-52 2,760 BMD
10 3 6 11,300 DMD
11* 2.8 32-44 + 25,722 DMD
12 8 48, 49 16,670 DMD
21* 2.2 18-44 + 39,318 DMD
22 13 45-48 3,573 BMD
23 1.4 3-7 14,490 DMD
24 0.8 34-54 + 21,850 DMD
25 2.6 13-37 + 6,710 DMD
26 5.4 8-55 33,732 DMD
28 4.8 43 + 10,000 DMD
29 6.7 2-36, 77 10,000 DMD
*Case 11 and case 21 are brothers; 
†Means the age of symptom onset; 
‡The remark of + means that the patient has a family history for DMD or BMD; 
§Plasma creatine kinase 
(CK) levels were measured in all patients at onset. CK, creatine kinase; BMD, Becker muscular dystrophy; DMD, Duchenne muscular dystrophy.
Fig. 1. Duplications of exons 3-7 of the dystrophin gene in one affected patient (case 23). (A) Electrophoregrams after MLPA in a control patient, (B) Electrophoregrams after 
MLPA in case 23.
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Fig. 3. The results of single exon PCR (A) and electrophoregrams after MLPA analysis (B) of exon 33 in the dystrophin gene of case 20. (A) Single exon PCR result. Lane 1 is 
from a control sample, and the band of lane 2 corresponds with exon 33 of case 20. (B) The arrow indicates absence of a peak corresponding to exon 33 in MLPA analysis.
Table 2. The MLPA results from two myopathic female patients and six female rela-
tives of five DMD patients
Case 
MLPA analysis of 
female carrier
Family  
relationship
Molecular analysis of  
the related male patient
Multiplex PCR MLPA
30 Del Ex18-44 Mother of  
cases 11, 21
Del Ex32-44 Del Ex18-44
31 Del Ex34-54 Mother of case 24 Not tested Del Ex34-54
32 Del Ex13-37 Mother of case 25 Not tested Del Ex13-37
33 Del Ex13-37 Sister of case 25 Not tested Del Ex13-37
34* Dup Ex61-77
35 Dup Ex43 Mother of case 28 Not tested Dup Ex43
36 Dup Ex43 Maternal aunt of 
case 28
Not tested Dup Ex43
37* Del Ex68
*Female carriers newly detected by MLPA to determine the cause of myopathy. Del, 
deletion; Dup, duplication; Ex, exon.
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Fig. 2. Deletions of exons 18-44 of the dystrophin gene in one affected patient (case 21) and his mother (case 30). These electrophoregrams show the MLPA sample after hy-
bridization with SALSA probe mix P034 (dystrophin gene exons 1-10, 21-30, 41-50, and 61-70). The deletions of exons 18-20 and 31-40 were detected after probe hybridiza-
tion with P035 (dystrophin gene exons 11-20, 31-40, 51-60, and 71-79), which is not shown. (A) Control, (B) Female carrier, (C) Case 21. 
formed to screen for deletions. Twelve patients (cases 1-12) had 
deletions of the dystrophin gene. Eight patients (cases 13-20) 
showed a normal pattern in the multiplex PCR. Full direct DNA 
sequencing of the dystrophin gene was performed for case 17, 
but the result was normal. MLPA analysis was performed in 11 
patients (cases 19-29), including two patients with a normal mul-
tiplex PCR pattern (cases 19, 20). Six patients (cases 20-22, 24-
26) had deletions of the dystrophin gene, and duplications were 
detected in three patients (cases 23, 28, 29, Table 1, Fig. 1). Seven 
patients (cases 13-19) who did not show any mutation on genet-
ic studies were diagnosed by muscle biopsy and immunohisto-
chemical analysis. 
  Two brothers (cases 11, 21) and their mother (case 30) were 
included in this study. While the elder brother (case 11) had de-
letions of exons 32-44 according to multiplex PCR, the younger Lee BL, et al.  •  Dystrophin Gene Analysis for Affected Patients and Carriers in Korea
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brother (case 21) and their mother (case 30) had deletions of 
exons 18-44, shown with the MLPA method (Fig. 2). In the other 
five female relatives (cases 31-33, 35, 36), the deletions or dupli-
cations were identical to that previously detected in the related 
male (Table 2). MLPA analysis was also able to detect deletions 
or duplications in two female myopathic patients (Table 2).
  MLPA analysis revealed a single exon deletion of the dystro-
phin gene in one patient (case 20), in whom conventional mul-
tiplex PCR analysis did not detect any deletions. We noted the 
absence of a peak corresponding to exon 33 and performed PCR 
amplification of the exon with a primer set designed for sequenc-
ing in order to confirm the deletion of the exon. PCR amplifica-
tion revealed a product of the correct size, indicating that the 
exon was present. However, sequencing analysis revealed a non-
sense mutation (c.4559G > T;Glu1520X) in the gene correspond-
ing to the last 3´ nucleotide of the left MLPA probe (Fig. 3, 4). 
The altered nucleotide was located precisely at the ligation site 
of the half-probes, sufficiently disrupting the ligation to appear 
as a deletion.
 
DISCUSSION
In this study, we used multiplex PCR from January 2003 to May 
2006 in 20 DMD/BMD patients and the MLPA technique from 
June 2006 to November 2010 in 11 patients, their six female rel-
atives, and two female myopathic patients to identify exonic re-
arrangements in the dystrophin gene. Twenty deletions and six 
duplications were identified (Tables 1, 2).
  Deletions in male patients can be easily detected using mul-
tiplex PCR, because two multiplex sets covering mutation hot-
spot regions could detect about 98% of all deletions (10, 11). 
However, the MLPA assay analyzes all 79 exons, thus detecting 
all exon scale deletions and larger size of deletions than those 
previously determined by multiplex PCR (13). Interestingly, we 
found different sizes of deletions in one family. The multiplex 
A
B
cDNA
sequence
Amino acid
sequence
Fig. 4. Direct DNA sequencing of exon 33. The arrow indicates the hemizygous G to 
T transversion at nucleotide 4558 in exon 33 (c.4558G > T;Glu1520X) of the dystro-
phin gene of case 20. (A) Control, (B) Case 20.
PCR revealed deletions of exons 32-44 in the older brother be-
fore the utilization of MLPA. The MLPA method revealed that 
the younger brother and the mother (cases 21, 30) had a longer 
deletion (exons 18-44) after three years. Hwa et al. (14) reported 
that none of the deletions found by multiplex PCR was missed 
by MLPA, and MLPA increased the deletion detection rate by 
5.7%. Although this is not a direct comparison, the MLPA may 
allow for more accurate determination of deletion size. 
  Among all 29 DMD/BMD patients, 17 (58.6%) were found to 
have exon deletions. With MLPA, the rate of deletions was 45.5% 
(5/11), which is lower than that estimated in previous reports, 
based mainly on European or American data (1, 3, 9, 15). In ad-
dition, the duplication rate was relatively higher (27.3%, 3/11). 
The deletion rate and the duplication rate were reported as 36.0% 
and 24.7%, respectively, in Taiwanese patients (14). Another 
study revealed a similar deletions rate of 34.3% in local Chinese 
patients (16). Those studies hypothesized that the discrepancies 
of frequencies of deletions and duplications compared to previ-
ous reports may have been due to the ethnic or regional differ-
ence (14-16). Although our result is similar to those results, it is 
limited for generalization by small sample size and should be 
further confirmed in larger studies.
  Deletions and duplications can happen almost anywhere in 
the dystrophin gene. However, one location towards the central 
part of the gene (exons 44-55) and the other site towards the 5´ 
end (exons 2-20) have been previously reported as the two hot-
spot regions (1, 3, 11). The 200-kb region covering intron 44, exon 
45, and intron 45 is known as the major deletion breakpoint re-
gion of the gene (3). In this study, most of deletions were con-
fined to the central hotspot region between exons 44 and 55 (n =  
9, 52.9% of deletions), followed by exons 2-20 (n = 3, 17.6% of 
deletions). Those data are in agreement with other studies (1, 3, 
15). In particular, in our BMD patients, deletions were arranged 
between exons 45 and 52, and three patients had deletions be-
tween exons 45-48. According to previous reports, distal rod de-
letions involving exons 45 to 48 result in a relatively high level of 
dystrophin and a mild BMD phenotype, while proximal dele-
tions tend to associate with a low level of dystrophin and a more 
severe phenotype (17, 18). In this study, two patients had only 
mild myalgia, while the other one patient was asymptomatic, 
with increased CK levels. All three patients maintained indepen-
dent ambulation ability and normal muscle strength beyond 
age 13.
  Since adopting the MLPA technique, we could identify muta-
tion of the dystrophin gene in six female relatives and two female 
myopathic patients. The previous performed multiplex PCR ap-
proach is not useful for detecting female carriers, because the 
deletions of dystrophin gene are masked by the amplification of 
the normal X chromosome. However, MLPA, a new method in-
volving quantitative analysis of all exons, allows for carrier de-
tection and can provide valuable information for genetic coun-Lee BL, et al.  •  Dystrophin Gene Analysis for Affected Patients and Carriers in Korea
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seling and prenatal diagnosis. In all female relatives, MLPA pro-
vided evidence of the same dystrophin gene mutations as those 
observed in the affected, related males. For one female carrier 
(case 36), we carried out prenatal diagnosis using amniotic flu-
id cells and confirmed that the fetus did not have any deletions 
or duplications in the dystrophin gene. The female carrier con-
fidently continued with her pregnancy. Recently, Wu et al. (19) 
reported that MLPA is a very promising prenatal diagnosis tech-
nique for congenital genetic diseases combined with short tan-
dem repeat analysis (STR) genotyping and linkage analysis. Us-
ing STR genotyping, the genomic DNA of the fetus was identi-
fied not to be contaminated by his mother’s DNA, because am-
niotic fluid cells are easily contaminated by blood cells from the 
mother. In addition, X-linkage analysis showed that only the X 
chromosome of the fetus comes from his mother. MLPA analy-
sis disclosed mutations in dystrophin genes in our two myo-
pathic female patients. Two-thirds of the mothers of affected 
males are thought to be female carriers, and approximately 8% 
of female carriers suffer from some degree of muscle weakness 
(8, 20, 21). Serum CK levels are elevated in approximately 45%-
70% of carriers, including those in our study, and the measure-
ment of serum CK is the most commonly used initial screening 
method for detecting carriers (21, 22). Although muscular weak-
ness was not prominent in our cases, one female (case 37) pre-
sented with intermittent myalgia, predominantly in the leg, and 
pseudohypertrophy of the calf muscle. Using MLPA analysis, we 
could confidently identify carrier individuals in female myopath-
ic patients who had no family history of dystrophinopathies. How-
ever, familial genetic analysis will provide the exact genetic infor-
mation for other family members and for genetic counseling.
  In the present study, we found a deletion of a single exon 
caused by point mutations in the oligo-binding domains. False-
positive MLPA results may be due to the presence of polymor-
phisms obstructing probe annealing, or they can occur if a se-
quence variation coincides with the probe binding regions and 
ligation site (13, 23, 24). Therefore, a confirmatory test by PCR 
or direct sequencing is necessary for cases with a single exon 
deletion detected by MLPA (13, 23). In the present study, we 
confirmed that the apparent exon 33 deletion observed in one 
patient (case 20) was caused by a novel nonsense mutation 
(c.4558G > T;Gln1520X) in the oligonucleotide hybridization 
region through direct DNA sequencing analysis. 
  For those patients with no exon deletions or duplications, full 
sequence analysis is the robust method for detecting small mu-
tations (25). However, in our study, one patient (case 17) showed 
no mutations using direct DNA sequencing of the dystrophin 
gene and was diagnosed via muscle biopsy. Some mutations 
remain unidentified, and complex rearrangements, which are 
thought to be pure intronic rearrangements or changes in the 
regulatory regions, are impossible to precisely define using rou-
tine molecular diagnostic techniques (3, 26). 
  Recently, a novel, custom high-density comparative genomic 
hybridization array (CGH), which analyzes copy number varia-
tion across the entire dystrophin gene, was designed (26-28). 
That method has the added advantages of detecting complex 
rearrangements and large scale intronic alterations, thereby of-
fering a slightly higher mutation detection rate than MLPA and 
other exon-based tests. However, it is apparent from the major-
ity of genetic studies that all mutations cannot be identified with 
standard molecular analysis. In those cases, a muscle biopsy 
may be helpful for protein studies and muscle RNA analysis to 
establish an accurate diagnosis.
  In this study, the overall mutation detection rate was 72.4% 
in DMD/BMD patients. The percentage of deletions in the dys-
trophin gene was lower, while the duplication rate was higher 
than data for a Caucasian population. However, our study should 
be further confirmed in future studies due to the small sample 
size. Since the time MLPA was introduced, it is possible to iden-
tify female carriers as well as deletions or duplications in the dys-
trophin gene, as we have demonstrated the mutations in six fe-
male relatives and two female myopathic patients. Our recom-
mendation is that genetic study for dystrophin gene analysis 
should begin with quantitative screening via MLPA, followed 
by full sequence analysis from genomic DNA. The MLPA-based 
array analysis system, recently developed as a simple, rapid and 
automated system, provides high-resolution and speed (29, 30). 
Therefore, we expect MLPA analysis to be enhanced by future 
technological improvements to further increase mutation de-
tection and reduce cost.
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